Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 11, 2016, Pages

  Elphick, Heather E ^a   Southern, Kevin W ^b  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CORTICOSTEROID; HYDROCORTISONE; ITRACONAZOLE; PYRROLE DERIVATIVE; ANTIFUNGAL AGENT;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIFUNGAL THERAPY; ASPERGILLUS FUMIGATUS; CYSTIC FIBROSIS; DRUG EFFECT; HUMAN; HYDROCORTISONE BLOOD LEVEL; LUNG FUNCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ADULT; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; CHILD; COMPLICATION; DRUG EFFECTS;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; CHILD; CYSTIC FIBROSIS; HUMANS;

EID: 84997079304     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002204.pub4     Document Type: Review

References (29)

1. Aaron SD, Vandemheen KL, Freitag A, Pedder L, Cameron W, Lavoie A, et al. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PloS One 2012;7(4):e36077. [CENTRAL: 842311; CFGD Register: PI253; CRS: 5500100000011271; 2729935; PUBMED: 22563440]
2. Cohen-Cymberknoh M, Blau H, Shoseyov D, Efrati O, Armoni S, Kerem E. Intravenous methylprednisolone pulse therapy vs. oral prednisone for allergic bronchopulmonary aspergillosis (ABPA) in CF [abstract]. Journal of Cystic Fibrosis 2008;7(Suppl 2):S58. [2729937]
3. Novartis An exploratory study to assess multiple doses of Omalizumab in patients with cystic fibrosis complicated by acute bronchopulmonary aspergillosis (ABPA). Clinicaltrials.gov (www.clinicaltrials.gov) (accessed 21/01/2013) 2008:ClinicalTrials.gov Identifier: NCT00787917. [CFGD Register: PI264; CRS: 5500100000010742; 2729939]
4. Proesmans M, Vermeulen F, Vreys M, Dupont LJ, De Boeck K. Treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis: antifungal therapy with inhaled amphotericin B [abstract]. Pediatric Pulmonology 2009;44(Suppl 32):349, Abstract no:392. [2729941]
5. Proesmans M, Vermeulen F, Vreys M, de Boeck K. Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. International Journal of Pediatrics 2010;2010(Article ID 376287):9 pages. [2729942; DOI: 10.1155/2010/376287]
6. Capewell S, Chapman BJ, Alexander F, Greening AP, Crompton GK. Corticosteroid treatment and prognosis in pulmonary eosinophilia. Thorax 1989;44(11):925-9.
7. Cystic Fibrosis Foundation. National Patient Registry. Annual Data Report [Bethesda, Maryland] 2000.
8. Denning DW, Van Wye JE, Lewiston NJ, Stevens DA. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest 1991;100(3):819.
9. Denning DW, Hanson LH, Perlman AM, Stevens DA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagnostic Microbiology and Infectious Disease 1992;15(1):21-34.
10. Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Chest 1999;116(3):639-46.
11. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
12. Hutchison ML, Govan JR. Pathogenicity of microbes associated with cystic fibrosis. Microbes and Infection 1999;1(12):1005-14. [MEDLINE: 10617932]
13. Lai HC, FitzSimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. The Lancet 2000;342(12):851-9.
14. Laufer P, Fink JN, Burns WT, Singer GF, Kalbfleisch JH, Greenberger PA. Allergic bronchopulmonary aspergillosis in cystic fibrosis. Journal of Allergy and Clinical Immunology 1984;73(1 Pt 1):44-8.
15. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B: safety data from a phase 2/3 clinical trial. Journal of Antimicrobial Chemotherapy 1991;28(Suppl B):83-91.
16. Mroueh S, Spock A. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Chest 1994;105(1):32-6.
17. Nepomuceno IB, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest 1999;115(2):364-70.
18. Purcell IF, Corris PA. Use of nebulised liposomal amphotericin B in the treatmenof Aspergillus fumigatus empyema. Thorax 1995;50(12):1321-3.
19. Rosenberg M, Patterson R, Roberts M, Wang J. The assessment of immunologic and clinical changes occurring during corticosteroid therapy for allergic bronchopulmonary aspergillosis. American Journal of Medicine 1978;64(4):599-606.
20. Safirstein BH, D'Souza MF, Simon G, Tai E, Pepys J. Five year follow-up of allergic bronchopulmonary aspergillosis. American Review of Respiratory Disease 1973;108(4):450-9.
21. Simmonds EJ, Littlewood JM, Evans EG. Cystic fibrosis and allergic bronchopulmonary aspergillosis. Archives of Disease in Childhood 1990;65(5):507-11.
22. Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. European Respiratory Journal 2002;20(1):127-33.
23. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, et al. A randomised trial of itraconazole in allergic bronchopulmonary aspergillosis. New England Journal of Medicine 2000;342(11):756-62.
24. Varkey B. Allergic bronchopulmonary aspergillosis: clinical perspectives. Immunology and allergy clinics of North America 1998;18(3):479-501.
25. Wark PA, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Epid GD, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: A randomised controlled trial. Journal of Allergy and Clinical Immunology 2003;111(5):952-7.
26. Wark P, Wilson AJ, Gibson PG. Azoles for allergic bronchopulmonary aspergillosis. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD001108.pub2]
27. Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD002204]
28. Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD002204.pub2]
29. Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 11. [DOI: 10.1002/14651858.CD002204.pub3]